Table 1.
General characteristics of the studied series, according to newly diagnosis or follow-up patient groups
| Characteristics | Total (n = 790, 100.0%) | Newly diagnosed (n = 124, 15.7%) | Follow-up (n = 666, 84.3%) | P value |
|---|---|---|---|---|
| Age (SD), years | 44.4 (13.1) | 41.7 (13.0) | 44.9 (13.1) | 0.016 |
| Ranges: | ||||
| 19-35 years | 25.7% | 36.8% | 23.6% | 0.025 |
| 36-50 years | 40.8% | 36.8% | 41.7% | |
| 51-65 years | 26.0% | 19.3% | 27.2% | |
| > 65 years | 7.4% | 7.0% | 7.5% | |
| Gender (female) | 68.9% | 63.7% | 69.8% | NS |
| Diagnosis delay (SD), years | 2.3 (4.9) | 2.2 (4.6) | 2.3 (5.0) | NS |
| Body mass index, kg/m2 | 24.8 (4.0) | 24.2 (3.3) | 25.0 (4.1) | 0.018 |
| Drug intake at time of the study visit (n): | ||||
| Average | 2.4 (1.2) | 1.8 (1.2) | 2.5 (1.2) | < 0.001 |
| 1 | 26.0% | 55.4% | 22.7% | < 0.001 |
| 2 | 33.3% | 24.6% | 34.3% | |
| 3 | 21.3% | 6.2% | 23.0% | |
| 4 | 14.5% | 9.2% | 15.1% | |
| 5 or more | 4.9% | 4.6% | 4.9% | |
| Drug intake at the time of the study visit (class): | ||||
| Benzodiazepines | 49.3% | 72.9% | 47.3% | < 0.001 |
| SSRI/SNRI | 34.9% | 15.3% | 36.6% | |
| Tricyclic antidepressants | 9.2% | 6.8% | 9.5% | |
| Antiepileptics | 2.8% | 1.7% | 2.9% | |
| Other medication | 3.7% | 3.4% | 3.7% | |
Values are expressed as arithmetic mean (SD).
NS = not significant; SSRI/SNRI = selective serotonin reuptake inhibitors/mixed action selective serotonin reuptake inhibitors or noradrenergics.